Inhibition of FGFR signaling with infigratinib improves linear bone growth in the female <i>Aga2/+</i> mouse model of osteogenesis imperfecta.

ABSTRACT: Osteogenesis imperfecta, a genetically heterogeneous disorder, is characterized by brittle bones with recurrent fractures as well as short stature. A recent study investigating cellular signaling in growth plate chondrocytes identified an increased expression of FGF receptors and elevated FGF signaling. We inhibited FGF receptor activation with the small molecule infigratinib in growing Aga2/+ mice and then characterized linear growth, cartilage growth plate histology, and bone morphometrics. Infigratinib treatment resulted in increased female femur length, increased growth plate lengths in both sexes, specifically in the proliferative zone, and reduced phospho-ERK1/2 as well as SOX9 expression in lower hypertrophic chondrocytes. Infigratinib had no impact on cortical bone but reduc

SUBMITTER: Kot A 

PROVIDER: S-EPMC12866916 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature